Sign up to save your podcasts
Or
Share Ditching Delay: GH001’s Instant Impact on Depression
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Ditching Delay: GH001’s Instant Impact on Depression
Connor Williams was shocked when the data came back for GH001. What could this mean for the future of treatment-resistant depression? Listen to his exclusive interview with Dr. Valcheva, the CEO of GH Research, to find out.
PODCAST TEAM
Producer: Devon Leaver
Editor: Dominique Guerra
Featuring: Dr. Velichka (Villy) Valcheva MD, CEO of GH Research moderated by Connor Williams, Senior Research Analyst at RTW Investments.
Don't forget to listen to part 1 of Connor’s discussion on treatment resistant depression and psychedelics with Stephanie Sirota, Managing Partner and Chief Business Officer at RTW Investments.
FOLLOW US
Love our podcast? Follow us on LinkedIn at RTW Investments, LP and check out our website for the latest updates and insights.
To make sure you never miss an episode, you can subscribe to the RTW podcast on Spotify, Apple Podcasts, Amazon Music, and most other podcast platforms.
CHAPTERS
00:00 – Introduction
01:09 – About GH Research
04:20 – Becoming CEO of GH Research
06:27 – The difference between GH001 and other psychedelics
11:37 – The difficulties of developing a scheduled substance
12:27 – Dealing with the stigma of psychedelics
15:31 – What else can GH001 treat?
17:26 – The future of GH Research
20:53 – Outro and Disclaimer
DISCLAIMER
This interview was given by Dr. Velichka (Villy) Valcheva MD, CEO of GH Research, and moderated by Connor Williams, Senior Research Analyst at RTW Investments. Statements reflect RTW's views and opinions as of the date hereof and not as of any future date. All expressions of opinion are subject to change without notice and are not intended to be a forecast of future events or results. The views expressed by guests are their own, and their appearance on the program does not imply an endorsement of them or any entity they represent.
View all episodes
By RTW Investments, LPConnor Williams was shocked when the data came back for GH001. What could this mean for the future of treatment-resistant depression? Listen to his exclusive interview with Dr. Valcheva, the CEO of GH Research, to find out.
PODCAST TEAM
Producer: Devon Leaver
Editor: Dominique Guerra
Featuring: Dr. Velichka (Villy) Valcheva MD, CEO of GH Research moderated by Connor Williams, Senior Research Analyst at RTW Investments.
Don't forget to listen to part 1 of Connor’s discussion on treatment resistant depression and psychedelics with Stephanie Sirota, Managing Partner and Chief Business Officer at RTW Investments.
FOLLOW US
Love our podcast? Follow us on LinkedIn at RTW Investments, LP and check out our website for the latest updates and insights.
To make sure you never miss an episode, you can subscribe to the RTW podcast on Spotify, Apple Podcasts, Amazon Music, and most other podcast platforms.
CHAPTERS
00:00 – Introduction
01:09 – About GH Research
04:20 – Becoming CEO of GH Research
06:27 – The difference between GH001 and other psychedelics
11:37 – The difficulties of developing a scheduled substance
12:27 – Dealing with the stigma of psychedelics
15:31 – What else can GH001 treat?
17:26 – The future of GH Research
20:53 – Outro and Disclaimer
DISCLAIMER
This interview was given by Dr. Velichka (Villy) Valcheva MD, CEO of GH Research, and moderated by Connor Williams, Senior Research Analyst at RTW Investments. Statements reflect RTW's views and opinions as of the date hereof and not as of any future date. All expressions of opinion are subject to change without notice and are not intended to be a forecast of future events or results. The views expressed by guests are their own, and their appearance on the program does not imply an endorsement of them or any entity they represent.